miR-24-3p Is Antiviral Against SARS-CoV-2 by Downregulating Critical Host Entry Factors
Viruses · 2024
DOI: 10.3390/v16121844 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Parrish Evers und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Biomolecular Sciences, University of Ottawa, Ottawa, ON K1N 6N6, Canada. Hauptthemen laut MEDLINE: MicroRNAs, SARS-CoV-2, Virus Internalization, COVID-19. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canadian Institutes for Health Research (CIHR), Natural Sciences and Engineering Council of Canada (NSERC).
Abstract (Originalsprache)
Despite all the progress in treating SARS-CoV-2, escape mutants to current therapies remain a constant concern. Promising alternative treatments for current and future coronaviruses are those that limit escape mutants by inhibiting multiple pathogenic targets, analogous to the current strategies for treating HCV and HIV. With increasing popularity and ease of manufacturing of RNA technologies for vaccines and drugs, therapeutic microRNAs represent a promising option. In the present work, miR-24-3p was identified to inhibit SARS-CoV-2 entry, replication, and production; furthermore, this inhibition was retained against common mutations improving SARS-CoV-2 fitness. To determine the mechanism of action, bioinformatic tools were employed, identifying numerous potential effectors promoting infection targeted by miR-24-3p. Of these targets, several key host proteins for priming and facilitating SARS-CoV-2 entry were identified: furin, NRP1, NRP2, and SREBP2. With further experimental analysis, we show that miR-24-3p directly downregulates these viral entry factors to impede infection when producing virions and when infecting the target cell. Furthermore, we compare the findings with coronavirus, HCoV-229E, which relies on different factors strengthening the miR-24-3p mechanism. Taken together, the following work suggests that miR-24-3p could be an avenue to treat current coronaviruses and those likely to emerge.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry and Biomolecular Sciences, University of Ottawa, Ottawa, ON K1N 6N6, Canada.
- Vaccine and Infectious Disease Organization (VIDO), University of Saskatchewan, Saskatoon, SK S7N 5E3, Canada.
- Department of Biochemistry, Microbiology, and Immunology, University of Saskatchewan, Saskatoon, SK S7N 5E3, Canada.
ORCID-Profile: Parrish Evers, Magen E Francis, John P Pezacki
Förderung
- Canadian Institutes for Health Research (CIHR)
- Natural Sciences and Engineering Council of Canada (NSERC)
Zitieren
APA
Evers, P., Uguccioni, S. M., Ahmed, N., Francis, M. E., Kelvin, A. A., & Pezacki, J. P. (2024). miR-24-3p Is Antiviral Against SARS-CoV-2 by Downregulating Critical Host Entry Factors. Viruses. https://doi.org/10.3390/v16121844
Vancouver
Evers P, Uguccioni SM, Ahmed N, Francis ME, Kelvin AA, Pezacki JP. miR-24-3p Is Antiviral Against SARS-CoV-2 by Downregulating Critical Host Entry Factors. Viruses. 2024. doi:10.3390/v16121844
BibTeX
@article{Evers2024,
author = {Evers, Parrish and Uguccioni, Spencer M and Ahmed, Nadine and Francis, Magen E and Kelvin, Alyson A and Pezacki, John P},
title = {miR-24-3p Is Antiviral Against SARS-CoV-2 by Downregulating Critical Host Entry Factors},
journal = {Viruses},
year = {2024},
doi = {10.3390/v16121844}
}
EUVIMED